Clinical Trial Supplies Market Research Report
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Clinical Trial Supplies Market, By Clinical Phase
7.1. Clinical Trial Supplies Market, by Clinical Phase, 2020-2030
7.1.1. Phase I
7.1.1.1. Market Revenue and Forecast (2016-2030)
7.1.2. Phase II
7.1.2.1. Market Revenue and Forecast (2016-2030)
7.1.3. Phase III
7.1.3.1. Market Revenue and Forecast (2016-2030)
7.1.4. Other
7.1.4.1. Market Revenue and Forecast (2016-2030)
Chapter 8. Global Clinical Trial Supplies Market, By Product & Services
8.1. Clinical Trial Supplies Market, by Product & Services, 2020-2030
8.1.1. Manufacturing
8.1.1.1. Market Revenue and Forecast (2016-2030)
8.1.2. Storage & Distribution
8.1.2.1. Market Revenue and Forecast (2016-2030)
8.1.3. Supply Chain Management
8.1.3.1. Market Revenue and Forecast (2016-2030)
Chapter 9. Global Clinical Trial Supplies Market, By End User
9.1. Clinical Trial Supplies Market, by End User, 2020-2030
9.1.1. Pharmaceutical
9.1.1.1. Market Revenue and Forecast (2016-2030)
9.1.2. Biologics
9.1.2.1. Market Revenue and Forecast (2016-2030)
9.1.3. Medical device
9.1.3.1. Market Revenue and Forecast (2016-2030)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2016-2030)
Chapter 10. Global Clinical Trial Supplies Market, By Therapeutic Use
10.1. Clinical Trial Supplies Market, by Therapeutic Use, 2020-2030
10.1.1. Oncology
10.1.1.1. Market Revenue and Forecast (2016-2030)
10.1.2. CNS Disorders
10.1.2.1. Market Revenue and Forecast (2016-2030)
10.1.3. Cardiovascular
10.1.3.1. Market Revenue and Forecast (2016-2030)
10.1.4. Infectious Disease
10.1.4.1. Market Revenue and Forecast (2016-2030)
10.1.5. Metabolic Disorders
10.1.5.1. Market Revenue and Forecast (2016-2030)
10.1.6. Others
10.1.6.1. Market Revenue and Forecast (2016-2030)
Chapter 11. Global Clinical Trial Supplies Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Clinical Phase (2016-2030)
11.1.2. Market Revenue and Forecast, by Product & Services (2016-2030)
11.1.3. Market Revenue and Forecast, by End User (2016-2030)
11.1.4. Market Revenue and Forecast, by Therapeutic Use (2016-2030)
11.1.5. U.S.
11.1.5.1. Market Revenue and Forecast, by Clinical Phase (2016-2030)
11.1.5.2. Market Revenue and Forecast, by Product & Services (2016-2030)
11.1.5.3. Market Revenue and Forecast, by End User (2016-2030)
11.1.5.4. Market Revenue and Forecast, by Therapeutic Use (2016-2030)
11.1.6. Rest of North America
11.1.6.1. Market Revenue and Forecast, by Clinical Phase (2016-2030)
11.1.6.2. Market Revenue and Forecast, by Product & Services (2016-2030)
11.1.6.3. Market Revenue and Forecast, by End User (2016-2030)
11.1.6.4. Market Revenue and Forecast, by Therapeutic Use (2016-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Clinical Phase (2016-2030)
11.2.2. Market Revenue and Forecast, by Product & Services (2016-2030)
11.2.3. Market Revenue and Forecast, by End User (2016-2030)
11.2.4. Market Revenue and Forecast, by Therapeutic Use (2016-2030)
11.2.5. UK
11.2.5.1. Market Revenue and Forecast, by Clinical Phase (2016-2030)
11.2.5.2. Market Revenue and Forecast, by Product & Services (2016-2030)
11.2.5.3. Market Revenue and Forecast, by End User (2016-2030)
11.2.5.4. Market Revenue and Forecast, by Therapeutic Use (2016-2030)
11.2.6. Germany
11.2.6.1. Market Revenue and Forecast, by Clinical Phase (2016-2030)
11.2.6.2. Market Revenue and Forecast, by Product & Services (2016-2030)
11.2.6.3. Market Revenue and Forecast, by End User (2016-2030)
11.2.6.4. Market Revenue and Forecast, by Therapeutic Use (2016-2030)
11.2.7. France
11.2.7.1. Market Revenue and Forecast, by Clinical Phase (2016-2030)
11.2.7.2. Market Revenue and Forecast, by Product & Services (2016-2030)
11.2.7.3. Market Revenue and Forecast, by End User (2016-2030)
11.2.7.4. Market Revenue and Forecast, by Therapeutic Use (2016-2030)
11.2.8. Rest of Europe
11.2.8.1. Market Revenue and Forecast, by Clinical Phase (2016-2030)
11.2.8.2. Market Revenue and Forecast, by Product & Services (2016-2030)
11.2.8.3. Market Revenue and Forecast, by End User (2016-2030)
11.2.8.4. Market Revenue and Forecast, by Therapeutic Use (2016-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Clinical Phase (2016-2030)
11.3.2. Market Revenue and Forecast, by Product & Services (2016-2030)
11.3.3. Market Revenue and Forecast, by End User (2016-2030)
11.3.4. Market Revenue and Forecast, by Therapeutic Use (2016-2030)
11.3.5. India
11.3.5.1. Market Revenue and Forecast, by Clinical Phase (2016-2030)
11.3.5.2. Market Revenue and Forecast, by Product & Services (2016-2030)
11.3.5.3. Market Revenue and Forecast, by End User (2016-2030)
11.3.5.4. Market Revenue and Forecast, by Therapeutic Use (2016-2030)
11.3.6. China
11.3.6.1. Market Revenue and Forecast, by Clinical Phase (2016-2030)
11.3.6.2. Market Revenue and Forecast, by Product & Services (2016-2030)
11.3.6.3. Market Revenue and Forecast, by End User (2016-2030)
11.3.6.4. Market Revenue and Forecast, by Therapeutic Use (2016-2030)
11.3.7. Japan
11.3.7.1. Market Revenue and Forecast, by Clinical Phase (2016-2030)
11.3.7.2. Market Revenue and Forecast, by Product & Services (2016-2030)
11.3.7.3. Market Revenue and Forecast, by End User (2016-2030)
11.3.7.4. Market Revenue and Forecast, by Therapeutic Use (2016-2030)
11.3.8. Rest of APAC
11.3.8.1. Market Revenue and Forecast, by Clinical Phase (2016-2030)
11.3.8.2. Market Revenue and Forecast, by Product & Services (2016-2030)
11.3.8.3. Market Revenue and Forecast, by End User (2016-2030)
11.3.8.4. Market Revenue and Forecast, by Therapeutic Use (2016-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Clinical Phase (2016-2030)
11.4.2. Market Revenue and Forecast, by Product & Services (2016-2030)
11.4.3. Market Revenue and Forecast, by End User (2016-2030)
11.4.4. Market Revenue and Forecast, by Therapeutic Use (2016-2030)
11.4.5. GCC
11.4.5.1. Market Revenue and Forecast, by Clinical Phase (2016-2030)
11.4.5.2. Market Revenue and Forecast, by Product & Services (2016-2030)
11.4.5.3. Market Revenue and Forecast, by End User (2016-2030)
11.4.5.4. Market Revenue and Forecast, by Therapeutic Use (2016-2030)
11.4.6. North Africa
11.4.6.1. Market Revenue and Forecast, by Clinical Phase (2016-2030)
11.4.6.2. Market Revenue and Forecast, by Product & Services (2016-2030)
11.4.6.3. Market Revenue and Forecast, by End User (2016-2030)
11.4.6.4. Market Revenue and Forecast, by Therapeutic Use (2016-2030)
11.4.7. South Africa
11.4.7.1. Market Revenue and Forecast, by Clinical Phase (2016-2030)
11.4.7.2. Market Revenue and Forecast, by Product & Services (2016-2030)
11.4.7.3. Market Revenue and Forecast, by End User (2016-2030)
11.4.7.4. Market Revenue and Forecast, by Therapeutic Use (2016-2030)
11.4.8. Rest of MEA
11.4.8.1. Market Revenue and Forecast, by Clinical Phase (2016-2030)
11.4.8.2. Market Revenue and Forecast, by Product & Services (2016-2030)
11.4.8.3. Market Revenue and Forecast, by End User (2016-2030)
11.4.8.4. Market Revenue and Forecast, by Therapeutic Use (2016-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Clinical Phase (2016-2030)
11.5.2. Market Revenue and Forecast, by Product & Services (2016-2030)
11.5.3. Market Revenue and Forecast, by End User (2016-2030)
11.5.4. Market Revenue and Forecast, by Therapeutic Use (2016-2030)
11.5.5. Brazil
11.5.5.1. Market Revenue and Forecast, by Clinical Phase (2016-2030)
11.5.5.2. Market Revenue and Forecast, by Product & Services (2016-2030)
11.5.5.3. Market Revenue and Forecast, by End User (2016-2030)
11.5.5.4. Market Revenue and Forecast, by Therapeutic Use (2016-2030)
11.5.6. Rest of LATAM
11.5.6.1. Market Revenue and Forecast, by Clinical Phase (2016-2030)
11.5.6.2. Market Revenue and Forecast, by Product & Services (2016-2030)
11.5.6.3. Market Revenue and Forecast, by End User (2016-2030)
11.5.6.4. Market Revenue and Forecast, by Therapeutic Use (2016-2030)
Chapter 12. Company Profiles
12.1. Almac Group
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Biocair
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Catalent, Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. KLIFO
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Movianto (Walden Group)
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. PCI Pharma Services
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Sharp
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Thermo Fischer Scientific, Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Marken
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Parexel International Corporation
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers